Your browser doesn't support javascript.
loading
Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective.
Riedmaier, Arian Emami; DeMent, Kevin; Huckle, James; Bransford, Phil; Stillhart, Cordula; Lloyd, Richard; Alluri, Ravindra; Basu, Sumit; Chen, Yuan; Dhamankar, Varsha; Dodd, Stephanie; Kulkarni, Priyanka; Olivares-Morales, Andrés; Peng, Chi-Chi; Pepin, Xavier; Ren, Xiaojun; Tran, Thuy; Tistaert, Christophe; Heimbach, Tycho; Kesisoglou, Filippos; Wagner, Christian; Parrott, Neil.
Afiliación
  • Riedmaier AE; DMPK and Translational Modeling, AbbVie Inc., North Chicago, Illinois, USA. arian.emamiriedmaier@abbvie.com.
  • DeMent K; Global DMPK, Takeda Pharmaceutical Co., Ltd., San Diego, California, USA.
  • Huckle J; Drug Product Technology, Amgen, Thousand Oaks, California, USA.
  • Bransford P; Modeling & Informatics, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
  • Stillhart C; Pharmaceutical R&D, Formulation & Process Sciences, F.Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Lloyd R; Computational & Modelling Sciences, Platform Technology Sci-ences, GlaxoSmithKline R&D, Ware, Hertfordshire, UK.
  • Alluri R; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Basu S; Pharmacokinetic, Pharmacodynamic and Drug Metabolism-Quantitative Pharmacology and Pharmacometrics (PPDM-QP2),Merck & Co, Inc., West Point, Pennsylvania, USA.
  • Chen Y; Department of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA.
  • Dhamankar V; Formulation Development, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
  • Dodd S; Formulation Development, Cyclerion Therapeu-tics Inc., Cambridge, Massachusetts, USA.
  • Kulkarni P; Chemical & Pharmaceutical Profiling, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Olivares-Morales A; Department of Pharmacokinetics and Drug Metabolism, AmgenInc, Cambridge, Massachusetts, USA.
  • Peng CC; Pharmaceutical Sciences, Roche Pharmaceutical Research andEarly Development, Roche Innovation Center, Basel, Switzerland.
  • Pepin X; Department of Pharmacokinetics and Drug Metabolism, AmgenInc, Cambridge, Massachusetts, USA.
  • Ren X; Drug Metabolism and Pharmacokinetics, Theravance Biopharma, South San Francisco, California, USA.
  • Tran T; New Modalities and Parenteral Development, PharmaceuticalTechnology & Development, Operations, AstraZeneca, Maccles-field, UK.
  • Tistaert C; Modeling & Simulation, PK Sciences, Novartis Institutes of Biomedical Research, East Hanover, New Jersey, USA.
  • Heimbach T; Computational & Modelling Sciences, Platform Technology Sci-ences, GlaxoSmithKline R&D, Collegeville, Pennsylvania, USA.
  • Kesisoglou F; Pharmaceutical Sciences, Janssen Research & Development, Beerse, Belgium.
  • Wagner C; PBPK & Biopharmaceutics, Novartis Institutes of Biomedical Research, Wayne, New Jersey, USA.
  • Parrott N; Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey, USA.
AAPS J ; 23(1): 6, 2020 Nov 26.
Article en En | MEDLINE | ID: mdl-33244667
ABSTRACT
An Erratum to this paper has been published https//doi.org/10.1208/s12248-020-00535-z.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: AAPS J Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: AAPS J Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos